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Abstract
At the early onset of the 20
th century, several studies already reported that the gray matter was implicated in the
histopathology of multiple sclerosis (MS). However, as white matter pathology long received predominant attention
in this disease, and histological staining techniques for detecting myelin in the gray matter were suboptimal, it was
not until the beginning of the 21
st century that the true extent and importance of gray matter pathology in MS
was finally recognized. Gray matter damage was shown to be frequent and extensive, and more pronounced in
the progressive disease phases. Several studies subsequently demonstrated that the histopathology of gray matter
lesions differs from that of white matter lesions. Unfortunately, imaging of pathology in gray matter structures
proved to be difficult, especially when using conventional magnetic resonance imaging (MRI) techniques. However,
with the recent introduction of several more advanced MRI techniques, the detection of cortical and subcortical
damage in MS has considerably improved. This has important consequences for studying the clinical correlates of
gray matter damage. In this review, we provide an overview of what has been learned about imaging of gray
matter damage in MS, and offer a brief perspective with regards to future developments in this field.
Background
For many years, focal inflammatory demyelination in the
white matter (WM) was considered the most important
pathological ‘hallmark’ of multiple sclerosis (MS). How-
ever, demyelination in the cerebral cortex was already
observed in early pathology studies by Sander (1898),
Dinkler (1904), Schob (1907) and Dawson (1916) [1-4].
After these initial, largely casuistic, descriptions of
demyelination in the gray matter (GM) of MS patients,
the topic was largely disregarded. This was mostly due
to difficulties involved with the visualization of cortical
GM lesions in the post mortem setting, in which con-
ventional histochemical staining procedures were
applied, as well as to a predominant attention for the
generally more conspicuous process of inflammatory
WM demyelination.
However, by the start of the 21
st century, the focus
within MS research slowly shifted back from WM to
GM. In 2003, when new immunohistochemical staining
techniques that improved the ex vivo detection of GM
damage had become available, the presence and extent
of GM demyelination was described in detail and patho-
physiological processes causing GM damage, as well as
its visualization with modern magnetic resonance ima-
ging (MRI) techniques, became central issues in MS
research (see Figure 1).
This review will focus on what has been learned in the
past decade of imaging GM pathology in MS. As will be
shown, visualization of GM demyelination was difficult
at first, but improved upon technical developments in
the field. An important question that now remains is
whether MRI visualization of GM pathology in MS is
sufficient, or whether further improvement is still
needed.
GM involvement in a WM disease
After the first pivotal reports of GM damage in MS in
the early 20th century, it was not until 1962 that Brow-
nell and Hughes reported that 26% of the macroscopi-
cally visible lesions found in their post mortem material
of 22 MS patients were (partly) located in or around the
cortical and subcortical GM [5]. Extensive involvement
of the cortex in MS patients was later confirmed in his-
topathology [6] and in a study combining post mortem
MRI and conventional histology [7].
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tion in tissue sections was difficult, as standard histo-
chemical myelin stains like luxol fast blue (LFB) were
not sufficiently adequate for visualization of changes in
GM myelin density. Detection of GM pathology with
conventional T2-weighted MRI also proved to be diffi-
cult because of the intrinsically low myelin density in
the cortex, which generates little contrast between nor-
mal GM and demyelinated GM lesions, and because of
the fact that cortical lesions may be small and partial
volume effects with cerebrospinal fluid in the sulci can
interfere with reliable lesion detection [7,8]. To improve
the detection of cortical lesions on MRI, newer techni-
ques like fast fluid-attenuated inversion recovery
(FLAIR) MR sequence were used [9,10]. FLAIR
improved lesion detection in the cortex and in (juxta)
cortical areas as compared to conventional T2-weighted
MRI [9-14]. However, the reported prevalence of corti-
cal lesions on MRI was still much lower than that
reported in post mortem studies [10].
Description and classification of GM pathology in MS
Histopathological detection of intracortical MS lesions
improved with the use of myelin protein immunohisto-
chemistry in the beginning of the 21
st century. Using
immunohistochemistry for myelin basic protein (MBP)
and proteolipid protein (PLP), Bö and colleagues shed
more definitive light on the extent and distribution of
cortical demyelination in MS [15,16]. In chronic MS
cases myelin loss was found in 26.5% of their systema-
tically examined areas of cerebral cortex [15]. The
investigators proposed a classification system for corti-
cal lesions which distinguished four different cortical
lesion types: the mixed GM-WM (type I) lesions and
the purely cortical (type II, III, and IV) lesions [16]
(see Figure 2).
The pathology of GM lesions generally differs consid-
erably from that of WM lesions. Lymphocyte infiltration,
complement deposition, and blood-brain-barrier disrup-
tion have not been detected in GM lesions, whereas
WM lesions are known to harvest substantial
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Figure 1 Timeline of GM imaging in MS. A schematic overview of developments in the field of GM imaging in MS from the beginning of the
20
th century until now. A, B, D) Reproduced from Kidd et al. [7], Kutzelnigg et al. [19], and Schmierer et al. [88] respectively, all with permission
from Oxford University Press. C) Reproduced from Cifelli et al. [100] with permission from John Wiley and Sons. E, F) Reproduced from Geurts et
al. [69] and Roosendaal et al. [126] respectively, both with permission of the Radiological Society of North America.
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Page 2 of 11inflammation [16-18]. Another pivotal study by Kutzel-
nigg and colleagues showed demyelination of the MS
cortex and reported extreme cases with more than 70%
of cortical demyelination [19]. Besides demyelination in
the cerebral cortex, demyelination was later also found
in the cerebellum [20], in deep gray matter structures
[21,22], and in the GM of the spinal cord [23].
Pathological studies demonstrated that cortical demye-
lination is most frequent and extensive in patients with
a longer disease duration (secondary progressive MS;
SPMS) and with a more progressive form of MS (pri-
mary progressive MS, PPMS), whereas it was found to
be rare in relapsing remitting MS patients (RRMS)
[19,21]. However, GM demyelination was recently found
in biopsy material of an early MS patient, even before
disseminated WM lesions on MRI became visible [24].
Although histopathological studies had improved as a
result of the new staining methods, GM lesions
remained extremely difficult to detect on conventional
MRI. For example, it was shown that T2-weighted and
FLAIR imaging detected only 3 to 5% of a total of 63
histopathologically defined cortical lesions [25]. Never-
theless, the (juxta)cortical lesions that were detected
with these MRI sequences were clearly associated with
cognitive impairment, epilepsy, depression, fatigue, and
physical disability in MS patients [26-32].
In parallel, MRI studies focused on imaging the nor-
mal appearing GM of MS patients (NAGM; i.e., GM
that looks normal on conventional T2-weighted MRI,
but might nevertheless be histopathologically abnormal)
using more advanced, quantitative MRI techniques.
These techniques are generally more sensitive to (subtle)
pathology in the GM than conventional MRI sequences
[33]. Clinically relevant abnormalities in the NAGM of
MS patients were reported with magnetization transfer
imaging (MTI) [34-37], T1-relaxometry [38,39], diffusion
tensor imaging (DTI) [40,41], and proton magnetic reso-
nance spectroscopy (MRS) [42-44] in both cortical and
subcortical GM areas in MS. These measured abnormal-
ities most likely reflect subtle tissue changes due to
lesions or independent from lesions.
To sum up, around the turn of the century, GM
pathology in MS became increasingly recognized as an
important pathological hallmark in this ‘typical’ WM
disease. The introduction of new histopathological stain-
ing methods improved the visualization of GM damage
and revealed that GM demyelination was frequent,
widespread, and more extensive in patients with longer
disease duration. The pathological substrate of GM
lesions was found to be different from WM lesions, as
GM lesions are largely non-inflammatory. On conven-
tional MRI, only a minority of GM lesions could initially
be visualized. However, these lesions were associated
with clinical deterioration. Besides cortical lesions, quan-
titative MRI also demonstrated clinically relevant
abnormalities in the NAGM of MS patients.
GM atrophy and cortical thinning
Whereas the detection of focal GM lesions was difficult
using conventional MRI measures, GM atrophy measure-
ments proved to be robust and reliable using standard
MRI sequences [33]. Automated methods to estimate
brain volume were reproducible, both within and
between research centres [45,46]. Decreased GM tissue
volume, as well as cortical thinning, were found in MS
patients compared to healthy age-matched controls and
were observed already early in the disease course and
across different MS types [47-59]. In a longitudinal study
it was shown that whole brain atrophy rates were similar
over time in stable Clinically Isolated Syndrome (CIS)
patients, but steadily increasing as diseased severity
increased (RRMS and SPMS) [60]. Interestingly, a signifi-
cant and disproportionate increase in GM atrophy occurs
in MS patients in more advanced disease stages [55,61],
while WM atrophy rates accumulate more constantly
over time [60]. GM atrophy and cortical thinning were
significantly associated with physical disability and cogni-
tive decline [47-50,55,56,62-66], and importantly, mea-
sures of GM atrophy showed stronger correlations with
clinical parameters than WM damage [56,60,61,66].
New imaging techniques to detect cortical GM lesions
In 1994, a new MRI sequence, the double inversion
recovery (DIR), was introduced. This technique provided
Figure 2 Pathological classification system of GM lesions in MS.
GM lesion classification system as proposed by Bo et al,. 2003. Type
1 lesions (A) extend through both white and gray matter. Type 2
lesions (B) are intracortical, having no contact with white matter or
with the surface of the brain. Type 3 lesions (C) extend inward from
the surface of the brain. Type 4 lesions (D) extend through the
whole width of the cortex without reaching into white matter.
Reproduced from Geurts and Barkhof [131] with permission from
Elsevier.
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WM in the healthy human subjects by suppression of
the signal from WM and the cerebrospinal fluid (CSF)
[67]. DIR proved to be superior in comparison to FLAIR
where it concerned intratentorial lesions and lesions
with low contrast on T2-weighted MR sequences [68].
However, it was not until several years later that DIR
was applied to image GM pathology in MS [69]. In
2005, MR imaging with a 3D DIR sequence demon-
strated increased intracortical lesion detection in the MS
brain, as well as improved distinction between juxtacor-
tical and mixed WM-GM lesions. A relative gain of
152% of DIR over FLAIR was described in the detection
of cortical lesions [69]. Using DIR at a higher field
strength (3T) led to an even further increase of detected
cortical lesions in MS patients [70].
A series of important scientific contributions by
Calabrese and colleagues subsequently confirmed histo-
pathology studies by reporting that intracortical lesions
detected on DIR are already present early in the disease
[71-74] and are found in both relapse-onset and PPMS
patients [74,75]. The investigators further showed that
cortical lesions are most frequently found in SPMS
patients, in patients of the male sex, and in patients who
also had IgG oligoclonal bands in the CSF [76,77]. A
relative sparing of the cortex was found for patients
with benign MS [72]. The presence of cortical lesions
was associated with clinical disability, brain volume loss
and/or cognitive impairment [73,75-79]. Longitudinal
DIR studies showed an increase in cortical lesion num-
b e ra n d / o ra ni n c r e a s ei nl e s i o ns i z eo v e rt i m e
[73,75,77,80].
These results notwithstanding, the use of different DIR
sequences and different lesion scoring criteria in differ-
ent research centres made the comparison of available
cortical lesion data in the literature challenging. There-
fore, in an attempt to improve consistency of cortical
lesion scoring between raters and centres using DIR,
international cortical lesion scoring guidelines were pro-
posed [81,82]. These DIR scoring guidelines were subse-
quently verified in the post mortem setting and showed
that although DIR is highly pathologically specific (90%
of cortical hyperintensities identified related to actual
lesions in post mortem tissue), the sensitivity of DIR is
rather poor [82]. Especially subpial cortical lesions were
found to be difficult to detect on DIR.
So far, no specific pathological properties were found
that determine whether cortical lesions become MRI-
visible or MRI-invisible. Instead, it was shown that the
visibility of cortical lesions on MRI is predominantly
determined by their size. Furthermore, MRI-visible cor-
tical lesions were strongly associated with a higher total
cortical lesion load in brain tissue specimens, which sug-
gests that when cortical lesions become visible on MRI,
they merely reflect ‘the tip of the pathological iceberg’
[83].
Other studies aiming to improve visualization of corti-
cal GM lesions used phase-sensitive inversion recovery
(PSIR) and 3D T1 weighted sequences [84,85]. Future
post mortem work will have to show whether sensitivity
and specificity for cortical GM lesions may further
improve when combinations of T1-based techniques,
PSIR and DIR are used, when compared to DIR alone.
Ideally, this would lead to a recommendation as to
which (combination of) technique(s) should be used to
optimally visualize (cortical) GM pathology in vivo, and
further increase our understanding about the role of
GM damage in clinicocognitive deterioration in MS.
High-field and ultrahigh-field MRI
With the introduction of (ultra) high-field MRI, signal-
to-noise ratio, spatial resolution, and image contrast
improved, which all benefited the detection of GM
lesions [86-88]. In vivo studies using 2D T2*-weighted
gradient-echo and 3D T1-weighted magnetization-pre-
pared rapid-acquisition GRE sequences at 7T or higher
were able to provide high-resolution anatomical images
of cortical lesions [89-91]. It was recommended that a
combination of MR sequences be used at higher field
strength, as different techniques may provide comple-
mentary information in the definition of cortical lesions
[92]. Furthermore, and this is new when compared to
standard field, it was shown that ultra high-field MRI
enables accurate visualization of subpial GM lesions
[15,88,91].
Non-neocortical GM damage
MRI and histopathology studies showed that atrophy
and demyelinated lesions do not only exist in the corti-
cal GM but also in other GM structures such as the tha-
lamus, hippocampus, caudaute, putamen, pallidum,
claustrum, hypothalamus, amygdala and substantia nigra
[21-23,42,93-105], see Figure 3. Hypothalamic lesions
were found to be numerous in a post mortem MS data-
set [96] and higher inflammatory activity of hypothala-
mic lesions was associated with a worse disease course
[97].
Of all the GM structures, the thalamus has been stu-
died most extensively with MRI [21,22,42,99-110]. One
of the reasons that the thalamus received broad atten-
tion is because of the extensive reciprocal connections
with the cortex and subcortical structures which makes
this brain structure particularly sensitive to pathological
changes in other areas of the brain [100]. Several studies
focused on the volume of non-neocortical GM struc-
tures and showed thalamic atrophy in all different MS
disease types [102-104,106-109,111-113] (see Figure 3).
In CIS patients, thalamic atrophy was already present
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mic fraction was more pronounced in RRMS patients
compared to SPMS patients [104]. Additionally, in a
longitudinal study thalamic atrophy was found to be
more pronounced in RRMS patients compared to regio-
nal cortical atrophy [111]. This indicates that neuronal
damage in the thalamus occurs early in the disease
course. In terms of clinical relevance, thalamic atrophy
Figure 3 Subcortical GM damage in MS. Subcortical atrophy, measured using FIRST (part of FSL 4.1: http://www.fmrib.ox.ac.uk/fsl/). Above:
Effect sizes of subcortical atrophy in a cohort of 120 early RRMS patients, six years post-diagnosis. Below: Two examples of segmented
subcortical structures in a healthy control (HC, above) and an age-matched RRMS patient (MS, below).
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Page 5 of 11has been associated with disability, cognitive impair-
ment, and fatigue [99,104,107,110]. Furthermore, thala-
mic atrophy was seen in paediatric MS patients and
PPMS patients as well [109,113,114]. Using quantitative
MR techniques, changes in the chemical composition of
thalamic tissue could be detected. A reduction of N-
acetylaspartate (NAA) in the thalamus was found with
MRS and is thought to reflect neuro-axonal loss
[42,100,102]. MTI showed a reduced magnetization
transfer ratio (MTR) in the thalamus, an abnormality
which was already found within the first five years of
the disease [101,104]. And also changes in thalamic DTI
measures were partly associated with disability, brain
volume, and lesion load [105].
The hippocampus was found to be a predilection site
for GM demyelination in MS [21,95,115]. In vivo, areas
of signal abnormality in the hippocampus were also
identified by using DIR [116], as well as increased levels
of myo-inositol using MRS [42]. In addition, hippocam-
pal atrophy was found in RRMS, SPMS, and PPMS
patients, imaged at 1.5T and 3T [117,118]. At 3T, atro-
phy was reported to start in the cornu ammonis 1
(CA1) region of the hippocampus in RRMS, only to
expand to other CA regions in more advanced stages of
the disease (SPMS) [118].
Besides structural differences in the MS brain, func-
tional changes can be studied as well by using e.g. func-
tional MRI (fMRI). Different cognitive paradigms for
task-fMRI have been used so far, as well as resting-state
fMRI. Several differences between healthy controls and
MS patients were found in terms of brain activation and
brain connectivity [119-125]. Some fMRI studies focused
on a particular GM brain structure or functional anato-
mical system rather than on a specific cognitive domain.
For example, reduced functional connectivity was
reported between the hippocampus and its anatomical
input c.q. target areas, including the anterior cingulate
gyrus, thalamus, and prefrontal cortex. These changes
were more pronounced in MS patients with hippocam-
pal atrophy, but were also detected in patients without
hippocampal volume loss [126]. Additionally, in a task-
specific fMRI study, differences in hippocampal function
during a memory encoding task were detected between
MS patients with and MS patients without cognitive
decline. These findings were independent of differences
in hippocampal volume and number of hippocampal
lesions [127] (see Figure 4).
To summarize, during the past few years, the number
of studies investigating GM damage in MS has tremen-
dously increased. GM atrophy and cortical thinning
were shown to be robust and reliable measures. GM
a t r o p h yc o r r e l a t e dm o r es t r o n g l yt h a nW Ma t r o p h y
with disability and cognitive impairment. New imaging
techniques, such as DIR, improved the detection of
cortical lesions in vivo. With the introduction of (ultra)
high-field MRI, the visualization of cortical lesions
improved even further. Recently published international
consensus guidelines for scoring cortical lesions on DIR
will likely increase the consistency between different
research groups, and will improve the comparability of
different DIR studies. Post mortem work demonstrated
that DIR is pathologically specific, but lacks sensitivity.
This means that many cortical lesions are still missed
and MRI detects only ‘the tip of the pathological ice-
berg’. Despite their under representation on MRI, corti-
cal lesions were shown to be clinically relevant. Both
imaging and histopathology studies showed that GM
damage in MS is not limited to the neocortex; the cere-
bellum, spinal cord, and non-neocortical GM structures
are affected as well.
A brief future perspective of GM imaging in MS
From a pathological point of view, it is clear that GM
damage is common, widespread, and different from
WM damage. A challenging next step is to investigate
the cause(s) of GM pathology. For example, whether
damage to the GM develops purely as a result of inflam-
matory demyelination in the WM or whether pathologi-
cal processes in these two compartments of the brain
are less connected than formerly thought, still remains
to be elucidated [128-130].
As discussed in this review, from the neuroimaging
perspective, MRI techniques have substantially improved
over the past years and several new imaging modalities
to better detect GM abnormalities are now available. It
is possible to visualize cortical lesions with DIR, T1-
based or phase-sensitive sequences, as well as with
(ultra) high-field MRI. Moreover, GM tissue loss can be
reliably measured with the help of conventional MR
sequences, and more subtle tissue changes can be
observed with quantitative MRI. Finally, the function of
specific GM structures or functional systems, as well as
functional and structural connectivity changes within
the brain can be imaged with MRI. With all these differ-
ent imaging techniques to visualize GM pathology in
vivo, it now remains to be determined which image
modality, or combination of imaging modalities, best
explains or predicts clinical symptomatology, and
whether these techniques can be reliably used to moni-
tor future treatment effects. Furthermore, the spatiotem-
poral relation between structural and functional
changes, as well as changes in network dynamics in the
brain as a consequence of disease will be difficult but
exciting topics for future research in this field. The past
few years of GM imaging research have seen tremen-
dous progress; with the knowledge and technology now
available, it is likely that ongoing joint efforts between
different fields of research will create an even greater
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near future.
Conclusions
What have we learned in GM imaging in MS?
▪ GM damage in MS is common and widespread,
especially in chronic MS;
▪ The underlying pathological correlates of GM
damage in MS are different from WM damage;
▪ GM pathology is present in all stages of the dis-
ease, but is more prominent in SPMS and PPMS
compared to RRMS;
▪ Although a relatively non-specific measure of
overall pathology, GM atrophy measurements are
reliable and robust and correlate strongly with dis-
ability and cognitive impairment (more so than WM
atrophy);
▪ Cortical lesions are of clinical relevance and are
associated with a worse physical and cognitive
performance;
▪ Cortical lesions have been difficult to visualize
with conventional MRI, but due to newer imaging
techniques (like DIR) lesion detection improved;
▪ Post mortem DIR verification showed high specifi-
city of DIR lesions and increased sensitivity com-
pared to conventional MR sequences; however, a
substantial number of cortical lesions is still missed
with in vivo MRI;
Figure 4 Non-neocortical GM damage: the hippocampus. A) Extensive hippocampal demyelination observed in post-mortem material.
Reproduced from Geurts et al. [95] with permission from the American Association of Neuropathologists Inc. B) In vivo detection of
hippocampal lesions using DIR imaging. Reproduced from Roosendaal et al. [116] with permission from John Wiley and Sons. C) Hippocampal
atrophy on high field MRI provides detailed information on the specific location in the hippocampus where atrophy is present. Reproduced from
Sicotte et al. [118] with permission from Oxford University Press. D) Anno 2011 it is besides structural changes also possible to study functional
changes in the hippocampus; the blue areas indicates reduced hippocampal activity in cognitively impaired MS patients compared to healthy
controls. Reproduced from Hulst et al. [127] with permission from John Wiley and Sons.
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lesion scoring will likely improve the comparability
of different DIR studies;
▪ (Ultra) high-field MRI holds promise for more
precise detection of cortical lesions, with maybe
even the possibility to categorize GM lesions in vivo
according to the pathological classification system
used post mortem; especially the detection of subpial
lesions (type III lesions) is likely to benefit from the
use of (ultra) high-field MR imaging;
▪ Non-neocortical GM damage is frequently
detected in histopathological studies as well as on
MRI. Thalamic and hippocampal abnormalities have
been studied most extensively and were shown to
correlate with clinical parameters;
▪ Besides structural changes in the GM of MS
patients, functional changes can be detected as well
by using fMRI; this should shed more light on the
relationship between functional and structural
changes in the MS brain in future studies.
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